Regulatory milestones

Celgene Corp. (NASDAQ:CELG) shed $2 to $53.67 last week after Japan's Ministry of Health, Labor and Welfare approved Revlimid lenalidomide to treat myelodysplastic syndromes (MDS) in patients with 5q chromosomal deletion. In June, Japan approved the thalidomide analog in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM).

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was off $0.62 to $6.02 last week after FDA extended by three months, to December, the PDUFA date for an sNDA for Acetadote IV acetylcysteine to treat non-acetaminophen acute liver failure. The specific PDUFA date is not disclosed...